매사추세츠의 암 (전체) 임상 시험
암 (전체) 관련 연구 100개가 매사추세츠 내 여러 지역에서 참여자를 모집하고 있습니다.
매사추세츠의 도시
공식 연구 텍스트(영어)
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Reliant Medical Group Inc, Worcester
피험자 모집 중3상
18세 ~ 100세 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT05920356Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes
- Mass General Brigham Cancer Institute, Boston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT07672769Multicenter Study for External Validation of the TB-NET Score
- Dana-Farber Cancer Institute, Boston
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT07903532A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- Mass General Brigham Cancer Institute, Boston
- Dana Farber Cancer Institute, Boston
피험자 모집 중1상
16세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT07197554A Study of YL242 in Subjects With Advanced Solid Tumors
- US-204, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT07197827Childhood Cancer Predisposition Study (CCPS)
- Dana Farber Cancer Institute, Boston
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT04511806RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Dana Farber Cancer Institute, Boston
- University of Massachusetts Chan Medical Center, Worcester
피험자 모집 중2상
18세 ~ 80세 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT07002034Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- Baystate Medical Center, Springfield
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT06580314Improving Care Delivery for Patients With Mental Illness and Cancer Across a Cancer Center Network
- Massachusetts General Hospital, Boston
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT07707362Pan Tumor Rollover Study
- Dana_Farber Cancer Institute (DFCI), Boston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 6. 업데이트됨 · NCT03899155A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
- Boston Medical Center, Boston
- Massachusetts General Hospital (MGH), Charlestown
피험자 모집 중1상건강한 지원자 환영
18세 이상 · 모든 성별 · 2026. 11. 6. 업데이트됨 · NCT07258836A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital (MG), Boston
피험자 모집 중1상
18세 ~ 99세 · 모든 성별 · 2026. 11. 6. 업데이트됨 · NCT06983743REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis
- Beth Israel Deaconess Medical Center, Boston
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT07410117A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Dana Farber/Harvard Cancer Center, Boston
- University of Massachusetts - UMass Chan Medical School, Worcester
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT06901531Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT07059884A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Boston Medical Center, Boston
- Lahey Hospital & Medical Center, Burlington
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06119581A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Massachusetts General Hospital, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT07578571Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- Massachusetts General Hospital / Dana-Farber Cancer Institute, Boston
- University of Massachusetts Memorial Medical Center, North Worcester
피험자 모집 중2/3상
전 연령 · 모든 성별 · 2026. 11. 2. 업데이트됨 · NCT03435796Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 2. 업데이트됨 · NCT06959706A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
- Dana Farber Cancer Center ( Site 4013), Boston
피험자 모집 중1/2상
1 Month – 17 Years · 모든 성별 · 2026. 10. 30. 업데이트됨 · NCT07630974A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- Dana-Farber Cancer Institute /ID# 271846, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 27. 업데이트됨 · NCT06953960A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Research Site, Boston
- Research Site, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 26. 업데이트됨 · NCT06835569Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 10. 23. 업데이트됨 · NCT02984761Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer
- Dana-Farber Cancer Institute, Boston
피험자 모집 중2상
2세 ~ 99세 · 모든 성별 · 2026. 10. 21. 업데이트됨 · NCT05783323Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
- Beth Israel Deaconess Medical Center ( Site 0107), Boston
- Dana-Farber Cancer Institute ( Site 0105), Boston
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 21. 업데이트됨 · NCT07405164Pembrolizumab, Ibrutinib and Rituximab in PCNSL
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 21. 업데이트됨 · NCT04421560Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
- Dana Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 19. 업데이트됨 · NCT06162221A Study of ASP3082 in Adults With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 14. 업데이트됨 · NCT05382559A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC
- Brigham and Women's Hospital, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 13. 업데이트됨 · NCT07725796A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 13. 업데이트됨 · NCT05123482Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 13. 업데이트됨 · NCT06993844Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- Dana-Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 9. 업데이트됨 · NCT05386108A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
- Massachusetts General Hospital /ID# 273608, Boston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 9. 업데이트됨 · NCT07023289Suprachoroidal Administration in Subjects With Metastases to the Choroid
- Massachusetts Eye and Ear, Boston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 8. 업데이트됨 · NCT06643884BostonGene-Integrated Genomic Registry (BIGR)
- BostonGene, Waltham
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 10. 7. 업데이트됨 · NCT04991922FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 7. 업데이트됨 · NCT05919264CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Dana Farber Cancer Institute, Boston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 6. 업데이트됨 · NCT03328078A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 3013), Boston
피험자 모집 중1/2상
1 Month – 17 Years · 모든 성별 · 2026. 10. 6. 업데이트됨 · NCT06941272PediRISE Feasibility
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
피험자 모집 중
17세 이하 · 모든 성별 · 2026. 10. 5. 업데이트됨 · NCT06283251A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- Beth Israel Deaconess Medical Center - Research, Boston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT07192471ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.